A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers

Sandesh C.S. Nagamani, MD1,2, Umang Agarwal, PhD3, Allison Tam, MD1, Mahshid Azamian, MD, MPH1, Ann McMeans, MS, RD2,3, Inka C. Didelija, MS3, Mahmoud A. Mohammad, MD3, and Juan C. Marini, DVM, PhD3,4,*

1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
2Texas Children’s Hospital, Houston, TX, USA
3USDA/Agricultural Research Service, Children’s Nutrition Research Center, Houston, TX, USA
4Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

Summary

**Purpose**—Benzoate and phenylbutyrate are widely used in the treatment of urea cycle disorders, but detailed studies on pharmacokinetics and comparative efficacy on nitrogen excretion are lacking.

**Methods**—We conducted a randomized, three arm, crossover trial in healthy volunteers to study pharmacokinetics and comparative efficacy of phenylbutyrate (NaPB; 7.15 g·m⁻²·BSA·day⁻¹), benzoate (NaBz; 5.5 g·m⁻²·BSA·day⁻¹), and a combination of two medications (MIX arm; 3.575 g NaPB and 2.75 g NaBz·m⁻²·BSA·day⁻¹) on nitrogen excretion. Stable isotopes were used to study effects on urea production and dietary nitrogen disposal.

**Results**—The conjugation efficacy for both phenylbutyrate and benzoate was 65%; conjugation was superior at the lower dose used in the MIX arm. Whereas NaPB and MIX treatments were more effective at excreting nitrogen than NaBz, nitrogen excretion as a drug conjugate was similar between phenylbutyrate and MIX arms. Nitrogen-excreted-per-USD was higher with combination therapy compared to NaPB.

**Conclusions**—Phenylbutyrate was more effective than benzoate at disposing nitrogen. Increasing phenylbutyrate dose may not result in higher nitrogen excretion due to decreased conjugation efficiency at higher doses. Combinatorial therapy with phenylbutyrate and benzoate has the potential to significantly decrease treatment cost without compromising the nitrogen disposal efficacy.
INTRODUCTION

The urea cycle is the main pathway in humans for the disposal of waste-nitrogen derived from catabolism of dietary and endogenous proteins. Deficiency of one of the enzymes or transporters required for ureagenesis (Figure S1) causes urea cycle disorders (UCDs), a group of inborn errors of metabolism characterized by a decreased ability to dispose nitrogen and subsequent accumulation of ammonia in tissues and blood. Hyperammonemia can have serious consequences, and if severe, can result in intellectual disability, neurocognitive deficits, and even coma and death. Thus, the main focus of treatment for UCDs is the prevention and treatment of hyperammonemia.

Nitrogen-scavenging medications, which use alternative pathways to dispose nitrogen, have become a standard-of-care for the prevention and treatment of hyperammonemia in UCDs. For long-term management, oral formulations of benzoate and phenylbutyrate are the commonly used alternative pathway therapies. Benzoate combines with glycine to form hippuric acid (HA). Phenylbutyrate, a prodrug, is converted to phenylacetate (PAA) by β-oxidation; PAA conjugates with glutamine to form phenylacetylglutamine (PAGN) (Figure 1). Because glutamine has two nitrogen atoms compared to one in glycine, theoretically, on a mole-per-mole basis, nitrogen-scavenging efficacy of phenylbutyrate should be twice that of benzoate. However, in vivo efficacy is dependent upon medication absorption, conversion into active metabolite, and the efficacy of conjugation with amino acids. The conversion of benzoate into HA has been estimated to range from 65% to virtually 100%. Similarly, the conversion of phenylbutyrate to PAGN ranges from 50% to over 90%.

To date, the comparative in vivo efficacy of phenylbutyrate and benzoate on nitrogen excretion in humans has not been systematically studied. In fact, detailed pharmacokinetic studies of either medication in individuals with UCDs were lacking until recently, when basic kinetic studies were performed with sodium phenylbutyrate as a part of studies comparing it to glycerol phenylbutyrate, a pre-prodrug. Moreover, even preclinical data on efficacy are lacking due to the absence of suitable models as animals other than primates conjugate glycine with phenylacetate. Despite the lack of evidence, the theoretical advantage of phenylbutyrate over benzoate is likely one of the reasons for the preferential use of phenylbutyrate formulations (sodium phenylbutyrate and glycerol phenylbutyrate) in the United States. This approach, however, increases the economic burden of therapy as phenylbutyrate formulations are far more expensive than benzoate. A direct comparison between phenylbutyrate and benzoate and exploring the utility of combinatorial therapy with both medications would be of value in devising cost-effective management strategies for UCDs. The goal of this randomized crossover study was to determine the pharmacokinetics of phenylbutyrate and benzoate, the efficacy of the medications on nitrogen excretion, and the potential utility of combination therapy with both medications.
MATERIAL AND METHODS

The study was conducted at Baylor College of Medicine (BCM), Texas Children’s Hospital (TCH), and Children’s Nutrition Research Center (CNRC), Houston, TX, USA. The study procedures were approved by the BCM Institutional Review Board. Informed consent was obtained from all participants. Healthy adult volunteers (age ≥18 years) were recruited. Individuals with the following were excluded from the study: 1) history of dietary protein intolerance, 2) history of liver diseases, 3) inability to follow the prescribed diet or undergo the isotopic infusions, 4) documented history of hyperammonemia (defined as plasma ammonia >100 μmol/L), 5) clinical or laboratory abnormality of Grade 3 or greater according to the Common Terminology Criteria for Adverse Events v.4.0 (CTCAE), and 6) any condition(s) not covered by the CTCAE, but in the opinion of investigators, constituted a severe condition. Pregnant or lactating women were not enrolled.

Study design

This was a randomized, three-arm, crossover study. Each arm was completed over a four-day period with a washout period of at least 7 days between any two of the treatment arms (Figure 2). The treatment sequence was randomized in a non-blinded manner. The treatment and doses of the medications used were as follows: 1) NaPB arm: phenylbutyrate 7.15 g•m⁻²•day⁻¹; maximum dose, 20 g•day⁻¹, 2) NaBz arm: benzoate 5.5 g•m⁻²•day⁻¹; maximum dose, 12 g•day⁻¹, and 3) MIX arm: phenylbutyrate and benzoate, 3.575 and 2.75 g•m⁻²•day⁻¹, respectively (half the dose used in the NaPB and NaBz arms). The treatments were designed to provide isomolar amount of drugs and the total daily dose was administered in three equally divided doses. The doses of medications used in the study is representative of the typical doses that are used in the management of adults with UCDs.¹⁰

On day 1 of study arm 1, detailed medical history review and physical examination were performed. Complete blood count, comprehensive metabolic panel, plasma ammonia, and urinalysis (safety laboratory measurements) were performed. Urine pregnancy test was performed on all females. Meals prepared at the CNRC to provide 0.8 g•kg⁻¹•day⁻¹ protein and 32 kcal•kg⁻¹•day⁻¹ were given for next three days. The standardized protein and caloric intake allowed for comparison of nitrogen excretion among the three arms. Subjects were randomized to a predetermined treatment sequence and the first dose of the appropriate medication was administered under supervision. Subjects took the study medication with meals for three days (08:00 breakfast; 13:00 lunch; 19:00 dinner) (Figure 2). Treatment period of three days was chosen to allow for metabolic adaptations to the study medication as previously published.¹¹ On day 3, subjects omitted the 19:00 dose of the medication to prevent interference with the analysis on day 4 from metabolite conjugates from the previous day. On day 4, at ~8:00 and after placing a catheter (Insyte Autoguard, Becton Dikinson, Franklin Lakes, NJ) on a superficial hand vein, a fasting blood sample was obtained for the determination of plasma amino acids and urea concentrations, background isotopic enrichments, basic metabolic profile, complete blood count, and plasma concentrations of phenylbutyrate, benzoate, PAGN, and HA. Urine was collected for measurements of urea, phenylbutyrate, benzoate, PAGN, and HA. At 0 hours, the test meal containing half of the
daily dietary allowance of protein (0.4 g•kg\(^{-1}\)) was provided by a commercial liquid meal replacement (Ensure Plus, Abbott, Abbot Park, IL) and \(^{15}\)N labeled spirulina (40 mg•kg\(^{-1}\); ISOTEC, Miamisburg, OH). Spirulina is a natural source of protein from cyanobacteria that contains ~50% true protein and all essential amino acids.\(^{12}\) A dose of 40 mg•kg\(^{-1}\) labeled \(^{15}\)N-labeled spirulina was estimated to result in dietary \(^{15}\)N enrichment of ~5 mole percent excess. The test meal, which was ingested in ~10 minutes, was followed by a dose of study medication and an intravenous bolus dose of urea tracer, \([^{13}\text{C}^{18}\text{O}]\text{urea}\) (6 mmol/subject; ISOTEC, Miamisburg, OH). Blood samples to determine concentrations and isotopic enrichments of the drugs and their conjugated products, as well as amino acids and urea were collected every 30 minutes for the first four hours and then hourly between hours 4 and 8 (Figure 2). Urine was collected in four 2-hour batched periods during the eight hour admission period. The subjects then received a meal with the rest of the daily allowance and were discharged; the urine collection continued at home for the next 16 hours for a total 24 h collection period. The procedures for the study arms 2 and 3 were identical to those performed in arm 1.

**Sample Analysis**

The concentrations of drugs\(^{13}\) and their conjugates as well as urea\(^{14}\) and amino acids\(^{15}\) were determined by mass spectrometry and quantitated based on the dilution of labeled internal standards as previously published (Supplementary Information). Total urinary nitrogen was determined using the micro-Kjeldahl method.\(^{16}\)

**Calculations**

Pharmacokinetic parameters, peak concentration (Cmax), time to achieve Cmax for drugs and their conjugated products (Tmax), and area under the curve for 8 h after drugs ingestion (AUC\(_{0-8}\)) were determined using previously published methodology.\(^{17}\) Urea production was determined by non-compartmental analysis after fitting a biexponential model to the \([^{13}\text{C}^{18}\text{O}]\text{urea}\) enrichment data.\(^{18,19}\)

The total amount of nitrogen conjugated by drugs was calculated by multiplying the weight of 24h urine, the concentration of the metabolite of interest, and the nitrogen content of the metabolite. We detected PAGN and HA in the urine of subjects during treatment arms in which they were not receiving phenylbutyrate or benzoate, respectively. Accordingly, these background values were subtracted from the values obtained during the treatment with phenylbutyrate and benzoate. The total amount of nitrogen conjugated was expressed as fraction of the test meal, by dividing by the total nitrogen content of the test meal. The conjugation of dietary nitrogen was calculated as the amount of \(^{15}\)N conjugated by multiplying the total amount of nitrogen conjugated by the respective \(^{15}\)N enrichment. For PAGN, the labeling of the amino and amido groups of glutamine was considered.

Efficacy of drug conjugation, the technical relationship between the drug and its effects, was determined by dividing the amount of nitrogen conjugated by the amount of drug provided (in a molar and gram basis).\(^{20}\) Efficiency, an economic concept which relates efficacy to resource use, was calculated by dividing the amount of nitrogen conjugated by the estimated cost of phenylbutyrate (24.7 USD/g) and benzoate (0.03 USD/g) at our institution.\(^{21}\)
**Statistical Analysis**

Data were analyzed using the proc mixed procedure of SAS (v. 9.4; SAS Institute, Cary, NC) with subject as the random variable of the model; thus comparisons were done within subject. If a statistically significant effect for a particular treatment arm was observed ($P < 0.05$), post hoc Tukey procedure was performed for multiple pairwise comparisons. Data are expressed as means±SEM.

**RESULTS**

Seven individuals (5 males, 2 females) were enrolled. The demographic characteristics and the treatment sequences are outlined in Table S1.

**Pharmacokinetics of phenylbutyrate, benzoate, and their conjugated products**

After a 3-day treatment adaptation, pharmacokinetics were determined following a single drug dose on day 4 (Table 1, Figure S2). $T_{\text{max}}$ for phenylbutyrate and benzoate were not different whether the drugs were given alone or in combination ($P > 0.28$). $T_{\text{max}}$ for PAA was greater than $T_{\text{max}}$ for phenylbutyrate ($P < 0.001$), and tended to be greater in the NaPB arm as compared to the MIX arm ($P = 0.086$). As expected, $C_{\text{max}}$ and $AUC_{0-8}$ were greater when the drugs were given alone as compared to half the dose in the MIX arm. The $C_{\text{max}}$ and $AUC_{0-8}$ of phenylbutyrate and PAA were ~2–3 times greater when subjects were on the NaPB arm than on the MIX arm. Benzoate $C_{\text{max}}$ and $AUC_{0-8}$ were ~4–5 times greater when subjects were on the NaBz arm than on the MIX arm.

For the conjugation products, $T_{\text{max}}$ for PAGN was greater than for HA ($P < 0.01$). For PAGN, no difference in $T_{\text{max}}$ was observed between the NaPB and MIX arms ($P = 0.104$); however, hippurate $T_{\text{max}}$ was greater on the NaBz arm than in the MIX arm ($P < 0.008$). As expected, $C_{\text{max}}$ and $AUC_{0-8}$ for PAGN and HA were greater when phenylbutyrate and benzoate were given solely in the NaPB and NaBz arms as compared to the MIX arm ($P < 0.014$) (Table 1, Figure S2). A similar pattern was detected for the conjugation of the drugs with $^{15}$N labeled glutamine and glycine resulting from the ingestion of the $^{15}$N labeled test meal (Table 1).

**Urinary excretion of phenylbutyrate, benzoate, and their conjugated products**

The urinary excretion of phenylbutyrate, PAA, and benzoate was negligible (Table 2). Urine contained an average of $0.8±0.1$ mmol/d of PAGN and $1.7±0.3$ mmol/d of HA even when phenylbutyrate and benzoate, respectively, were not administered. After adjusting for these background values, the efficacy of conjugation, i.e., percent of phenylbutyrate dose recovered as PAGN and percent of benzoate dose recovered as HA in 24h urine were determined. The efficacy of conjugation (~65%) was similar for phenylbutyrate and benzoate when given as the sole treatments ($P=0.59$); however conjugation efficacy of phenylbutyrate was greater with the lower dose administered in the MIX arm as compared to the NaPB arm ($P < 0.044$). Similar trend was observed for benzoate ($P = 0.058$). A treatment effect ($P < 0.004$) was observed for the total amount of nitrogen excreted as conjugated products. NaPB and MIX treatments were more effective at conjugating and excreting nitrogen than the NaBz treatment (Table 2). However, no differences ($P = 0.19$) among the
three treatment arms was detected for the conjugation and excretion of $^{15}$N originating from the test meal (Table 2).

The efficacy of nitrogen conjugation and excretion was greater for the NaPB and MIX arms as compared to NaBz arm regardless of whether it was expressed on a per molar ($P < 0.004$) or per gram basis ($P = 0.032$) (Table 2). Nitrogen excretion as a drug conjugate was similar between the NaPB and the MIX arms, suggesting that combinatorial therapy could be as effective as therapy with NaPB. The efficiency of drug utilization (i.e., the amount of drug conjugated per dollar), however, was higher for the NaBz arm, followed by the MIX arm (Table 2).

**Effect of benzoate and phenylbutyrate on plasma amino acids**

There was no treatment effect on glutamine ($P = 0.15$) or glycine ($P = 0.13$) AUC$_{0-8}$ (Figure S3). A treatment effect, however, was detected for leucine AUC$_{0-8}$ ($P < 0.01$), which showed a reduction in subjects on the NaPB treatment. This was not evident for the other branched chain amino acids and other amino acids analyzed. The exception was tryptophan which showed a strong treatment effect ($P < 0.001$), with a reduction in AUC$_{0-8}$ in response to phenylbutyrate ($P < 0.001$; Figure S3). The ingestion of the $^{15}$N labeled test meal resulted in the $^{15}$N enrichment of all plasma amino acids which peaked around 3–4 h (data not shown). Substantial $^{15}$N amino acid enrichments were still observed 8 h after the test meal (data not shown).

**Effect of phenylbutyrate and benzoate on urea metabolism and total urinary nitrogen excretion**

There was no treatment effect on plasma urea concentration ($P = 0.16$) and urea production ($P = 0.80$) for any of the three treatment arms (Table 3). Likewise, there was no effect of treatment on total nitrogen ($P = 0.67$) or urea-nitrogen excretion ($P = 0.74$). Total urinary nitrogen excretion accounted for ~67% of the dietary nitrogen and urinary urea nitrogen accounted for ~65.5% of the total urinary nitrogen. Similarly, there was no treatment effect on urea $^{15}$N excretion ($P = 0.94$); on average urea excretion accounted for ~15% of the test meal nitrogen (Table 3).

**DISCUSSION**

In early 1980s, Saul Brusilow and Mark Batshaw made the serendipitous discovery of the utility of benzoate and phenylacetate for nitrogen disposal in UCDs. Currently, benzoate and formulations of phenylbutyrate are widely used in the long-term management of UCDs. Benzoate is available as a generic compound and is widely used as a food preservative; however, it has not been specifically approved by the United States Food and Drug Administration for the treatment of urea cycle disorders, which can sometimes pose a challenge for procuring prescription coverage. Whereas generic formulations of phenylbutyrate exist, for the most part, the availability of phenylbutyrate formulations is restricted. In the United States, the trade marked formulations of both sodium phenylbutyrate and glycerol phenylbutyrate are marketed by the same pharmaceutical company. In addition to the standard formulations of sodium phenylbutyrate, a taste-masked
granule formulation is also available in Europe and Canada, but not in the US.\textsuperscript{25,26} Over the past two decades, nitrogen-scavenging medications have become a standard-of-care in the treatment of UCDs and their use, at least in part, has contributed to the increased survival.\textsuperscript{2,27} However, the cost of treatment and access to medications are far from ideal.\textsuperscript{9} In patients who are able to get medications, the increase in number of pills and side effects associated with higher doses of medications can affect compliance.\textsuperscript{28} Whereas chronic treatment with phenylbutyrate in UCDs has generally been safe, phenylbutyrate affects many physiologic processes through its actions on transcription, inhibition of histone deacetylation, and modulation of endoplasmic reticulum stress, amongst others.\textsuperscript{29–31} Few of these off-target effects, like decrease in the plasma levels of branched-chain amino acids, may be of direct relevance in the management of UCDs.\textsuperscript{32} Understanding the comparative efficacy of nitrogen-scavenging medications and exploring combinatorial therapy would be an important first step in devising effective and affordable treatment regimens for UCDs.

In this study, we demonstrate that the efficacy of phenylbutyrate to conjugate and excrete nitrogen was greater than that of benzoate. However, as expected, none of the drugs conjugated completely and the efficacy of drug conjugation with its target amino acid at the highest dose of each drug was ~65%. Although some other metabolites may also be excreted\textsuperscript{33}, quantitatively they seem to be negligible. Neutral loss scans of urine by MS/MS, to detect the loss of the phenyl ring from unknown molecules, allowed us to identify phenylbutyrylglutamine; however, due to its low abundance we did not attempt to quantify this compound. Interestingly, the conjugation efficacy was greater when lower doses of phenylbutyrate and benzoate were used in the MIX arm. A likely reason for this observation was the lack of linearity in the pharmacokinetics of the drugs. Under the assumption of first order kinetics, doubling the dose of the drugs should result in a doubling of the Cmax and AUC; however, phenylbutyrate, PAA, and benzoate Cmax and AUC were significantly greater than expected when phenylbutyrate and benzoate were given as sole treatments as compared to half of these doses in the MIX arm. Moreover, as phenylbutyrate and benzoate conjugate different amino acids, the greater efficacy of conjugation with the MIX treatment may be due to the availability of substrate amino acids. An important finding from this study is that combination therapy using benzoate and phenylbutyrate could be as effective as a higher dose of phenylbutyrate. Due to its low cost, the inclusion of benzoate in the MIX arm virtually halved the cost per unit of nitrogen conjugated and excreted without reducing the efficacy of the treatment when compared to the NaPB arm.

The influx of dietary amino acids peaks approximately 3–4 h after a meal, which agrees with our observation using the \textsuperscript{15}N labeled test meal.\textsuperscript{34,35} Because the drugs were provided with the test meal, the greater efficacy of phenylbutyrate may also be due, at least in part, to a closer match between its pharmacokinetics and the kinetics of protein and amino acid digestion, absorption, and metabolism. However, we could not detect differences in the conjugation and excretion of \textsuperscript{15}N between the drugs or among the treatments.

There was no treatment differences in urea production among the three treatment arms and urea production in this study was comparable to our previous studies in control subjects consuming a diet that provided 0.6 g protein•kg\textsuperscript{−1}•d\textsuperscript{−1} and receiving phenylbutyrate.\textsuperscript{36}
Likewise, no differences among the treatments were found for urea nitrogen, \(^{15}\text{N}\) urea nitrogen and total nitrogen urinary excretion.

Because benzoate is widely present in foods as a preservative, it was not surprising to find HA in the urine of subjects not receiving benzoate. However, PAGN was also present in the urine of subjects not receiving phenylbutyrate. It is likely that endogenous PAA, generated by a minor pathway of phenylalanine disposal, was responsible for the appearance of this metabolite in urine.\(^{37}\) Regardless, basal levels of these two metabolites need to be considered when determining the efficiency of drug conjugation in future studies.

A limitation of this study is that it was conducted in healthy subjects. A major goal in the management of UCDs is the control of ammonemia and thus the effect of these drugs on plasma ammonia concentration is central to their therapeutic function.\(^{38}\) Due to the fact that ammonemia is well-controlled in healthy subjects, this endpoint was not assessed. Previous studies on phenylbutyrate metabolism were conducted in fasted and drug naïve individuals or in metabolically adapted subjects who were fed small frequent meals.\(^{36,39,40}\) A strength of the present study is that the drugs were studied after a 3 day adaptation period and in conjunction with a meal, which better represents the clinical scenario in the management of individuals with UCDs. An additional strength of the study was the use of \(^{15}\text{N}\) spirulina to determine the conjugation and excretion of dietary nitrogen, and thus determining for the first time, the fate of exogenous nitrogen when alternative pathways for nitrogen disposal are elicited.

In summary, on a molar basis, phenylbutyrate was more efficacious than benzoate at conjugating and disposing of nitrogen. The inclusion of both drugs resulted in a reduction of treatment cost without compromising the amount of nitrogen conjugated. The differences found in the pharmacokinetics between the two drugs may be utilized to devise cost-effective management strategies that maximize the efficacy of drug conjugation and at the same time increasing the cost-effectiveness of the therapy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by federal funds from the USDA–Agricultural Research Service under cooperative agreement 58-3092-5-001, the National Institute of Child Health and Human Development (R03 HD078447) and the Urea Cycle Disorders Consortium (UCDC) (U54 HD061221). UCDC is a part of Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), NCATS. This consortium is funded through collaboration between NCATS, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the NIH. The project described was also supported by Clinical Translational Core of the Baylor College of Medicine IDDRC grant 1 U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the USDA, the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the NIH. SC5N was supported by the C5D from the Doris Duke Charitable Foundation (grant 2013095). AT was supported by the T32 GM07526-40 Medical Genetics Research Fellowship Program.
References

1. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. N Engl J Med. 1984; 310:1500–5. [PubMed: 6717540]

2. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001; 138:S46–54. discussion S54–5. [PubMed: 11148549]

3. Ah Mew N, et al. Urea Cycle Disorders Overview. In: Pagon RA, , et al., editorsGeneReviews(R). Seattle (WA): 1993.

4. Mitch WE, Brusilow S. Benzoate-induced changes in glycine and urea metabolism in patients with chronic renal failure. J Pharmacol Exp Ther. 1982; 222:572–5. [PubMed: 7108765]

5. Simell O, Sipila I, Rajantie J, Valle DL, Brusilow SW. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res. 1986; 20:1117–21. [PubMed: 3099249]

6. Lee B, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. Mol Genet Metab. 2010; 100:221–8. [PubMed: 20382058]

7. James MO, Smith RL, Williams RT, Reidenberg M. The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species. Proc R Soc Lond B Biol Sci. 1972; 182:25–35. [PubMed: 4403084]

8. Jones AR. Some observations on the urinary excretion of glycine conjugates by laboratory animals. Xenobiotica. 1982; 12:387–395. [PubMed: 6753356]

9. Cederbaum S, Lemons C, Batshaw ML. Alternative pathway or diversion therapy for urea cycle disorders now and in the future. Mol Genet Metab. 2010; 100:219–20. [PubMed: 20462778]

10. Haberle J, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012; 7:32. [PubMed: 2262880]

11. Marini JC, et al. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients. Am J Clin Nutr. 2011; 93:1248–54. [PubMed: 21490144]

12. Becker EW. Micro-algae as a source of protein. Biotechnology Advances. 2007; 25:207–210. [PubMed: 17196357]

13. Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. Analytical Biochemistry. 2000; 280:242–249. [PubMed: 10790306]

14. Beylot M, et al. Determination of (13C) urea enrichment by gas chromatography/mass spectrometry and gas chromatography/isotope ratio mass spectrometry. Biol Mass Spectrom. 1994; 23:510–3. [PubMed: 7918692]

15. Marini JC. Quantitative analysis of 15N-labeled positional isomers of glutamine and citrulline via electrospray ionization tandem mass spectrometry of their dansyl derivatives. Rapid Communications in Mass Spectrometry. 2011; 25:1291–1296. [PubMed: 21491530]

16. Kirk PL. Kjeldahl method for total nitrogen. Analytical Chemistry. 1950; 22:354–358.

17. Urso R, Blardi P, Giorgi G. A short introduction to pharmacokinetics. European Review for Medical and Pharmacological Sciences. 2002; 6:33–44. [PubMed: 12708608]

18. Matthews DE, Downey RS. Measurement of Urea Kinetics in Humans - a Validation of Stable Isotope Tracer Methods. American Journal of Physiology. 1984; 246:E519–E527. [PubMed: 6742113]

19. Marini JC, Lee B, Garlick PJ. In vivo urea kinetic studies in conscious mice. J Nutr. 2006; 136:202–6. [PubMed: 16365083]

20. Mackenzie R, Dixon AK. Measuring the effects of imaging: An evaluative framework. Clinical Radiology. 1995; 50:513–518. [PubMed: 7656516]

21. Palmer S, Torgerson DJ. Economic notes: definitions of efficiency. BMJ. 1999; 318:1136. [PubMed: 10213735]
22. Batshaw ML, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med. 1982; 306:1387–92. [PubMed: 7078580]

23. Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science. 1980; 207:659–61. [PubMed: 6243418]

24. Brusilow SW, Valle DL, Batshaw ML. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979; 2:452–454. [PubMed: 89510]

25. Kibleur Y, Dobabella D, Barth M, Brassier A, Guffon N. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane(R) (Sodium Phenylbutyrate) taste-masked granules. Paediatr Drugs. 2014; 16:407–15. [PubMed: 24962711]

26. Koren G, Rieder MJ, Amitai Y. Averting the foul taste of pediatric medicines improves adherence and can be lifesaving - Pheburane(R) (sodium phenylbutyrate). Patient Prefer Adherence. 2016; 10:2141–2144. [PubMed: 27799750]

27. Enns GM. Nitrogen sparing therapy revisited 2009. Mol Genet Metab. 2010; 100(Suppl 1):S65–71. [PubMed: 20202877]

28. Shchelochkov OA, et al. Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectives. Mol Genet Metab Rep. 2016; 8:43–7. [PubMed: 27493880]

29. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011; 11:227–49. [PubMed: 21902286]

30. Kolb PS, et al. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol. 2015; 61:45–52. [PubMed: 25660369]

31. Kusaczuk M, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyric Acid: simple structure - multiple effects. Curr Pharm Des. 2015; 21:2147–66. [PubMed: 25557635]

32. Burrage LC, et al. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metab. 2014; 113:131–5. [PubMed: 25042691]

33. Kasumov T, et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab Dispos. 2004; 32:10–9. [PubMed: 14709615]

34. Gaudichon C, et al. Net postprandial utilization of [\textsuperscript{15}N]-labeled milk protein nitrogen is influenced by diet composition in humans. Journal of Nutrition. 1999; 129:890–895. [PubMed: 10203566]

35. Bos C, et al. Postprandial kinetics of dietary amino acids are the main determinant of their metabolism after soy or milk protein ingestion in humans. Journal of Nutrition. 2003; 133:1308–1315. [PubMed: 12730415]

36. Marini JC, et al. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients. American Journal of Clinical Nutrition. 2011; 93:1248–1254. [PubMed: 21490144]

37. Stein WH, Paladini AC, Hirs CHW, Moore S. Phenylacetylglutamine as a constituent of normal human urine. Journal of the American Chemical Society. 1954; 76:2848–2849.

38. Lee B, et al. Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. Genetics in Medicine. 2015; 17:561–568. [PubMed: 25503497]

39. Darmaun D, et al. Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am J Physiol. 1998; 274:E801–7. [PubMed: 9612237]

40. Comte B, et al. Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. Journal of Mass Spectrometry. 2002; 37:581–590. [PubMed: 12112740]
Figure 1. Alternative pathways for nitrogen disposal
With a block in ureagenesis, excretion of conjugates of amino acids can serve as an alternative mechanism for disposal of nitrogen. Benzoate and phenylacetate can be conjugated with glycine and glutamine, respectively to generate hippuric acid and phenylacetylglutamine. The nitrogen atoms scavenged by these medications is depicted by grey circles. Whereas one molecule of benzoate scavenges one atom of nitrogen, one molecule of phenylacetate scavenges two atoms of nitrogen.
Figure 2. Study design and procedures
Every subject was crossed-over to receive all three study medications, i.e., phenylbutyrate, benzoate and combination of phenylbutyrate and benzoate at half the dose. (H&P - history and physical examination; Safety labs - complete blood count, comprehensive metabolic panel, plasma ammonia, and urinalysis; * safety labs in study arms 2 and 3 were repeated only if abnormalities were noted on safety labs from the Day 4 of the preceding study arm or if the washout period was greater than 28 days from the preceding treatment arm). On day 4, after consuming the test meal (0.4 g protein/kg) labeled with $^{15}$N Spirulina, the subjects were administered the corresponding drugs and a urea tracer ($^{13}$C$^{18}$O urea). Blood and urea were sampled as indicated.
Table 1

Pharmacokinetics of phenylbutyrate, benzoate, and their conjugated products in healthy volunteers after a 3 day adaptation period to sodium phenylbutyrate (NaPB arm), sodium benzoate (NaBz arm) or a combination of both drugs (Mix arm)

| Drugs  | NaPB arm | MIX arm | NaBz arm | P <  
|--------|---------|--------|----------|------
| PB     |         |        |          |      
| Cmax (μmol/L) | 726.8 (61.3) | 333.5 (75.8) | 0.001 |      
| Tmax (h)   | 1.5 (0.4) | 1.5 (0.2) | 1.0 |      
| AUC<sub>0-8</sub> (μmol/L) | 1802.6 (215.9) | 662.1 (105.3) | 0.001 |      
| PAA    |         |        |          |      
| Cmax (μmol/L) | 211 (18) | 83.3 (10.8) | 0.001 |      
| Tmax (h)   | 3.2 (0.3) | 2.7 (0.3) | 0.086 |      
| AUC<sub>0-8</sub> (μmol/L) | 817.7 (83) | 248.9 (37.9) | 0.001 |      
| Bz     |         |        |          |      
| Cmax (μmol/L) | 39.7 (14.4) | 217.2 (65.1) | 0.016 |      
| Tmax (h)   | 1.4 (0.2) | 1.6 (0.4) | 0.28 |      
| AUC<sub>0-8</sub> (μmol/L) | 72.9 (9.6) | 301.7 (77.8) | 0.021 |      
| Conjugated Products | | | |      
| PAGN  |         |        |          |      
| Cmax (μmol/L) | 207.9 (15.6) | 120.6 (10.4) | 0.001 |      
| Tmax (h)   | 3.7 (0.2) | 3.2 (0.2) | 0.104 |      
| AUC<sub>0-8</sub> (μmol/L) | 1004.4 (71.7) | 489.5 (36) | 0.001 |      
| HA     |         |        |          |      
| Cmax (μmol/L) | 155.0 (20.2) | 218.1 (23.4) | 0.014 |      
| Tmax (h)   | 1.5 (0.2) | 2.2 (0.3) | 0.008 |      
| AUC<sub>0-8</sub> (μmol/L) | 392.3 (35.6) | 641.2 (70.3) | 0.002 |      
| Conjugated <sup>15</sup>N Products | | | |      
| 2-[<sup>15</sup>N] PAGN | | | |      
| Cmax (μmol/L) | 1.44 (0.35) | 0.88 (0.22) | 0.010 |      
| Tmax (h)   | 3.93 (0.07) | 3.86 (0.21) | 0.76 |      
| AUC<sub>0-8</sub> (μmol/L) | 5.59 (1.78) | 3.25 (0.87) | 0.061 |      
| 5-[<sup>15</sup>N] PAGN | | | |      
| Cmax (μmol/L) | 2.95 (0.71) | 1.93 (0.44) | 0.026 |      
| Tmax (h)   | 4.07 (0.28) | 3.56 (0.31) | 0.066 |      
| AUC<sub>0-8</sub> (μmol/L) | 12.30 (3.08) | 6.95 (1.69) | 0.015 |      
| 2&5-[<sup>15</sup>N] PAGN | | | |      
| Cmax (μmol/L) | 0.67 (0.09) | 0.46 (0.07) | 0.060 |      
| Tmax (h)   | 3.64 (0.14) | 3.14 (0.39) | 0.234 |      
| AUC<sub>0-8</sub> (μmol/L) | 2.75 (0.38) | 1.52 (0.20) | 0.006 |
|         | NaPB arm | MIX arm | NaBz arm | P <      |
|---------|----------|---------|----------|----------|
| Cmax (μmol/L) | 2.48 (0.49) | 3.12 (0.43) | 0.026    |
| Tmax (h)   | 1.71 \(^b\) (0.24) | 2.29 \(^b\) (0.31) | 0.047    |
| AUC0-8 (μmol/L) | 5.82 (0.88) | 8.27 (1.11) | 0.002    |

Values depict means and (standard errors of the mean). Cmax-maximal plasma concentration; Tmax-Time to achieve Cmax; AUC0-8 – area under the curve from time 0 (predose) to 8h; PB- phenylbutyrate; PAA – phenylacetate; Bz – benzoate; PAGN – phenylacetylglutamine; HA-hippuric acid

\(^a,b\) Tmax was also compared across the three arms. Values without a common superscript within a section differ P < 0.05
Table 2
Urinary excretion of phenylbutyrate, benzoate, and their conjugated products in healthy volunteers after a 3 day adaptation period to sodium phenylbutyrate (NaPB arm), sodium benzoate (NaBz arm) or a combination of both drugs (Mix arm)

| Drugs       | NaPB arm | MIX arm | NaBz arm | P <  
|-------------|----------|---------|----------|--------
| PB          |          |         |          |        
| μmol/24 h   | 32.3 (6.1) | 4.1 (1.4) |          | 0.003  
| % of dose   | 0.13 (0.03) | 0.03 (0.01) |          | 0.009  
| PAA         |          |         |          |        
| μmol/24 h   | 40.3 (10.5) | 7.9 (1.4) |          | 0.014  
| % of dose   | 0.16 (0.04) | 0.06 (0.01) |          | 0.017  
| Bz          |          |         |          |        
| μmol/24 h   | 7.2 (0.9) | 6.5 (1.5) |          | 0.59   
| % of dose   | 0.06 (0.01) | 0.02 (0.01) |          | 0.001  
| Conjugated Products | | | | 
| PAGN        |          |         |          |        
| mmol/24 h   | 15.3 (2.3) | 9.3 (0.8) |          |        
| % of dose   | 61.5 (8.5) | 74.4 (5.4) |          | 0.044  
| HA          |          |         |          |        
| mmol/24 h   | 10.5 (1.7) | 16.4 (3.1) |          | 0.033  
| % of dose   | 83.8 (12.0) | 66.1 (11.6) |          | 0.058  
| Total N     |          |         |          |        
| mmol/24 h   | 30.7a (4.5) | 29.0a (3.3) | 16.4b (3.1) | 0.004 
| g N/24 h    | 0.43a (0.06) | 0.41a (0.05) | 0.23b (0.04) | 0.004 
| % test meal | 8.74a (1.19) | 8.20a (0.69) | 4.65b (0.79) | 0.004 
| Conjugated 15N Products | | | | 
| 2-[15N] PAGN, μmol/24 h | 43.9 (10.2) | 37.1 (7.2) |          | 0.59   
| 5-[15N] PAGN, μmol/24 h | 142.0 (22.7) | 101.1 (11.1) |          | 0.15   
| 2&5-[15N] PAGN, μmol/24 h | 38.9 (6.2) | 26.7 (4.4) |          | 0.063  
| [15N] HA, μmol/24 h | 164.0 (30.1) | 253.9 (55.7) |          | 0.060  
| Total 15N   |          |         |          |        
| μmol/24 h   | 0.26 (0.04) | 0.36 (0.06) | 0.25 (0.06) | 0.19   
| mg N/24 h   | 3.95 (0.64) | 5.34 (0.83) | 3.79 (0.84) | 0.19   
| % test meal | 1.62 (0.27) | 2.14 (0.24) | 1.51 (0.31) | 0.19   
| Conjugation efficacy | | | | 
| mg N/mmol drug | 17.2a (2.4) | 16.3a (1.6) | 9.25b (1.6) | 0.004  
| mg N/g drug   | 92.5a (12.8) | 98.6a (9.4) | 64.2b (11.3) | 0.032  
| Conjugation efficiency | | | | 
| mg N/dollar  | 3.7c (0.5) | 7.1b (0.7) | 2445.4a (429.7) | 0.001  

Genet Med. Author manuscript; available in PMC 2018 August 25.
Values without a common superscript within a row differ $P < 0.05$
Table 3

Urea metabolism and total urinary nitrogen excretion in healthy volunteers after a 3 day adaptation period to sodium phenylbutyrate (NaPB arm), sodium benzoate (NaBz arm) or a combination of both drugs (Mix arm)

|                          | NaPB       | MIX        | NaBz       | P  |
|--------------------------|------------|------------|------------|----|
| N intake, g/d            | 9.81 (0.56)| 9.81 (0.56)| 9.81 (0.56)| -  |
| Plasma urea, AUC_{0-8} (mmol/L) | 23.6 (2.2) | 26.3 (2.3) | 25.5 (3.1) | 0.16 |
| Urea production, μmol•kg^{-1}•h^{-1} | 192 (14)   | 200 (15)   | 197 (26)   | 0.80 |
| Urinary N, g/d           | 6.47 (0.54)| 6.81 (0.63)| 6.38 (0.56)| 0.67 |
| % N excreted from daily intake | 65.6 (3.6) | 70.5 (6.5) | 65.1 (4.6) | 0.48 |
| Urinary Urea N, g/d      | 4.16 (0.64)| 4.69 (0.69)| 4.20 (0.58)| 0.74 |
| Urea N as a % total urinary N | 63.6 (6.7) | 67.7 (5.6) | 65.1 (5.3) | 0.88 |
| Urinary urea-^{15}N, g/d | 37.0 (4.9) | 38.0 (3.8) | 36.3 (5.0) | 0.94 |
| ^{15}N as % of test meal | 15.2 (2.1) | 15.5 (1.1) | 14.7 (1.8) | 0.93 |